Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$9.63 USD
-0.32 (-3.22%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $9.53 -0.10 (-1.04%) 5:32 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Brokerage Reports
Addex Therapeutics Ltd. Sponsored ADR [ADXN]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Neurosterix Spinout With Marquee Investors; Upgrading to Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ADXN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
ADX71149 Data in 2Q24; Eurostars Grant Awarded; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Research Collaboration Extended; 2Q22 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Equity Financing Complete; Cash Runway Lengthened; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Clinical Program Discontinuation; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Blepharospasm Trial Inconclusive; 1Q22 Financials; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Phase 2 Enrollment Completed; Pipeline Expands; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Blepharospasm Phase 2 Data Near-Term; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Multiple Clinical Catalysts; Runway Lengthened; Reducing PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Phase 2 Trial Advancing; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Indivior Research Collaboration Extension; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Seminal mGluR2 Publication Opens Intriguing Lines of Inquiry; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Pivotal Phase 2b/3 Trial Begins Screening Patients; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
ADX71149 Phase 2 Epilepsy Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Rescues Synaptic Plasticity in Dystonia Models; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
Dipraglurant Pivotal Trial Initiation Imminent; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Addex Therapeutics Ltd. Sponsored ADR
Industry: Medical - Drugs
An Underrated Leader in Allosteric Modulation; Initiating at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|